ArticleScientific reports2025
Survival analysis of PLWH on antiretroviral therapy in Henan Province from 2004 to 2024.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
There is a significant gap in data regarding the survival time and the factors influencing the survival of people living with HIV (PLWH) undergoing antiretroviral therapy (ART) in Henan Province, a region severely impacted by the AIDS epidemic.Investigating survival and influencing factors after ART can provide valuable insights to enhance patient management strategies and improve the prognosis for PLWH.This retrospective cohort study compiled case data and follow-up records of PLWH receiving ART at the Infectious Disease Hospital of Henan Province between 2004 and 2024. Survival curves were generated using the Kaplan-Meier method, and both univariate and multivariate Cox proportional hazards models were employed to identify factors influencing survival outcomes. Among the 4,307 study participants, a total of 251 (5.83%) patients died. The overall cumulative survival rate to the observation endpoint was 80%. The multifactorial Cox proportional risk regression modeling analysis of the primary outcomes showed that patients aged > 60 years at diagnosis of HIV/AIDS (HR = 4.706, 95% CI: 2.175 ~ 10.180), transmission route of heterosexual (HR = 1.403, 95% CI: 1.021 ~ 1.928) and blood transmission (HR = 1.855, 95% CI:1.206 ~ 2.855), patients with CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.